Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CFI-402411 in advanced solid tumors
NCT04521413Phase 2Active, not recruiting
- Sponsor
- Treadwell Therapeutics
- Start
- Aug 2020
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of CFI-402411 in solid tumor (advanced stage) (5 arms), sponsored by Treadwell Therapeutics. Primary endpoints: Incidence of adverse events of CFI-402411 as a single agent and at the recommended phase 2 dose (RP2D) at 48 months, Incidence of adverse events with CFI-402411 in combination with pembrolizumab and at the RP2D at 48 months and 2 more. Started Aug 2020; status: active, not recruiting.
02
Drugs
CFI-402411
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04521413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04521413.